LAWSUITS NEWS & LEGAL INFORMATION
FDA Reviews Saxagliptin (Onglyza and Kombiglyze XR) For Heart Failure Risk
Were you looking for Saxagliptin - Onglyza and Kombiglyze XR Side Effects lawsuits?
Washington, DC: The Food and Drug Administration (FDA) has requested clinical trial data from the manufacturer of saxagliptin to investigate a possible association between use of the type 2 diabetes drug and heart failure.
The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.
The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.
At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.
Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.
Last updated on
The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.
The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.
At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.
Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.
Legal Help
If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.Last updated on
DIABETES MEDICATION SIDE EFFECTS LEGAL ARTICLES AND INTERVIEWS
Ozempic Linked to Muscle and Bone Loss
Just Say NOzempic
Sen. Warren Raises the Alarm over Catalent/Novo Nordisk Merger
January 8, 2025
“'You've got the shrinks!' cried Mr Twit.” Roald Dahl’s "The Twits" tells the story of a deliciously dreadful old couple who torment each other (and their pet monkeys) with malicious pranks, including one where Mr. Twit gaslights his wife into believing that she’s shrinking. READ MORE
Just Say NOzempic
December 19, 2024
As the list of side effects from Ozempic and similar weight loss drugs lengthens, celebrities are quitting the GLP-1 drugs. It's a no-brainer: would you risk blindness, stomach paralysis, suicidal thoughts and more serious health issues to lose 20 pounds? And gain the weight back once you stop taking the drug? And lose your good looks? READ MORE
Sen. Warren Raises the Alarm over Catalent/Novo Nordisk Merger
November 1, 2024
On October 10, U.S. Senator Elizabeth Warren sent a letter to Federal Trade Commission (FTC) Chair Lina Khan, urging the FTC to closely review a proposed merger between Novo Nordisk and Catalent. Catalent is one of the very few suppliers that provide specialized development and manufacturing services to GLP-1 manufacturers. The letter urges the FTC to block the deal if it could hurt Americans by limiting competition and raising the price of life-saving medicine. Not coincidentally, killing competition might also limit the development of drugs without the dangerous side effects of Ozempic. READ MORE
READ MORE Drugs/Medical Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News
READ MORE Personal Injury Settlements and Legal News